EBS240927P7500
- 0.80
- 0.000.00%
Emergent BioSolutions Newsroom
Emergent Bio Gains After U.S. Govt. Order for Smallpox Therapy
12 Health Care Stocks Moving In Thursday's Intraday Session
Express News | Emergent BioSolutions Inc - Contract Has Maximum Potential Value of $568 Million
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA (Brincidofovir) to Support National Preparedness Efforts
Express News | Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional Tembexa® (Brincidofovir) to Support National Preparedness Efforts
Monkeypox concept stocks Emergent (EBS.US) obtained a $0.4 billion vaccine order, with a rise of over 8% at the beginning of the trading session.
Emergent Biosolutions earlier stated that it has received approximately 0.4 billion US dollars in combined orders for smallpox, anthrax, and monkeypox vaccine products, to be delivered in 2024 and 2025.
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday
Sector Update: Health Care
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Investors Await Economic Data
Emergent Biosolutions Shares Rise 16% on Orders Secured for Smallpox, Monkeypox Vaccines
Express News | Emergent BioSolutions Confirms Approximately $400 Million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
'Mpox Cases Double In Los Angeles County, Health Officials Urge Vaccination; Los Angeles County Public Health Officials Report Increase, Recommend Prevention Measures' - Pasadena Now
Biden On Sudan Says End This War Now; Let's Move Quickly To Face Mpox Outbreak In Africa
U.S. to Donate 1M Mpox Shots to Address Outbreak in Africa: Report
President Biden Will Announce Donation Of 1M MPox Vaccine Doses, At Least $500M To African Countries To Support Their Response To Outbreak
CDC Says No Cases Of Clade IA Mpox Have Been Reported Outside Central African Countries Where Clade IA MPVX Is Endemic
Emergent BioSolutions (NYSE:EBS) Pulls Back 17% This Week, but Still Delivers Shareholders Strong 101% Return Over 1 Year
US To Stay Committed In Bringing Mpox Outbreak Under Control
Rodman & Renshaw Reiterates Buy on Emergent BioSolutions, Maintains $16 Price Target
Emergent BioSolutions Analyst Ratings